These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 11513164

  • 21. Infliximab for ulcerative colitis: the need for adequately powered placebo-controlled trials.
    Rutgeerts P.
    Am J Gastroenterol; 2002 Oct; 97(10):2488-9. PubMed ID: 12385428
    [No Abstract] [Full Text] [Related]

  • 22. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab.
    Pierik M, Vermeire S, Steen KV, Joossens S, Claessens G, Vlietinck R, Rutgeerts P.
    Aliment Pharmacol Ther; 2004 Aug 01; 20(3):303-10. PubMed ID: 15274667
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Is keeping the colon the ultimate marker of success in ulcerative colitis?
    Nguyen GC, Prather CM.
    Gastroenterology; 2009 Oct 01; 137(4):1204-6. PubMed ID: 19717125
    [No Abstract] [Full Text] [Related]

  • 27. Controversies with aminosalicylates in inflammatory bowel disease.
    Lim WC, Hanauer SB.
    Rev Gastroenterol Disord; 2004 Oct 01; 4(3):104-17. PubMed ID: 15359211
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Is infliximab effective for induction of remission in patients with ulcerative colitis?
    Lichtenstein GR.
    Inflamm Bowel Dis; 2001 May 01; 7(2):89-93. PubMed ID: 11383596
    [No Abstract] [Full Text] [Related]

  • 32. Infliximab in the treatment of steroid-dependent ulcerative colitis.
    Armuzzi A, De Pascalis B, Lupascu A, Fedeli P, Leo D, Mentella MC, Vincenti F, Melina D, Gasbarrini G, Pola P, Gasbarrini A.
    Eur Rev Med Pharmacol Sci; 2004 May 01; 8(5):231-3. PubMed ID: 15638236
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Infliximab for ulcerative colitis.
    Chey WY, Shah A.
    J Clin Gastroenterol; 2005 May 01; 39(10):920; author reply 920. PubMed ID: 16208122
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Response to infliximab in atypical pyoderma gangrenosum associated with ulcerative colitis.
    Fernández A, Velasco A, Prieto V, Canueto J, Alvarez A, Rodríguez A.
    Am J Gastroenterol; 2008 Nov 01; 103(11):2951-2. PubMed ID: 19032482
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Editorial: prior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitis.
    Hendy P, Hart A.
    Aliment Pharmacol Ther; 2015 Jan 01; 41(1):149. PubMed ID: 25483435
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.